Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia

T cell acute lymphoblastic leukemia (T-ALL) is caused by clonal expansion of variant T cell progenitors and is considered as a high risk leukemia. Contemporary single chemotherapy has a limited effect due to dynamic and versatile properties of T-ALL. Here IRAK1/4 inhibitor and ABT-737 were co-encaps...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaoyan, Wang, Lin, Qiu, Yining, Zhang, Bingyu, Hu, Zhenhua, Jin, Runming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673049/
https://www.ncbi.nlm.nih.gov/pubmed/29184402
http://dx.doi.org/10.2147/IJN.S146875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673049/
https://www.ncbi.nlm.nih.gov/pubmed/29184402
http://dx.doi.org/10.2147/IJN.S146875

Ejemplares similares